Type 2 diabetes mellitus and inflammation: Prospects for biomarkers of risk and nutritional intervention
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Obesity is a major risk factor for type 2 diabetes mellitus (T2DM), which is a significant health problem worldwide. Active disease is associated with low-grade chronic inflammation resulting in part from the activation of the innate immune system. In obesity, this activation leads to the release of pro-inflammatory cytokines such as tumor necrosis factor-α, interleukin-1β and interleukin-6 that block major anabolic cascades downstream of insulin signaling and thus disrupt insulin homeostasis and action. Cytokines also trigger the production of acute-phase reactants such as C-reactive protein, plasminogen activator inhibitor-1, serum amyloid-A, and haptoglobin. The elevated synthesis of pro-inflammatory cytokines and acute-phase proteins (inflammatory network) characterizes the early (or pre-clinical) stages of T2DM and exhibits a graded increase with the disease progression. Current evidence suggests that understanding inflammatory networks can point to new biomarkers that may permit capturing the interaction between genetic and environmental risk factors in the pathogenesis of T2DM. Such biomarkers have a significant public health potential in the prediction of disease occurrence beyond risk factors presently monitored, such as family history, lifestyle assessment and standard clinical chemistry profiles. Furthermore, inflammatory markers may assist in the evaluation of novel strategies for prevention, particularly in relation to micronutrients. This review discusses the current knowledge linking T2DM risk to inflammatory signaling pathways interacting with the innate immunity system and the prospect of inflammatory markers serving as molecular targets for prevention and/or biomarkers for early risk prediction of T2DM. The potential of micronutrients replenishment to improve insulin action by attenuating inflammation is also evaluated in the context of the public health relevance of this approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wild, S., Roglic, G., Green, A., Sicree, R., & King, H. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1047 · Cited by 15,297
Inflammation and metabolic disorders
Hotamisligil, G. S. (2006) · Nature · doi:10.1038/nature05485 · Cited by 9,199 · cited 7×
“These cytokines are derived primarily from macrophages and can directly enhance insulin resistance in adipocytes, muscle and liver cells.(11,17) Macrophages infiltrate the expanding adipose tissue in obesity to remove dying cells and contribute to tissue angiogenesis.”
BackgroundInfluentialAcute-Phase Proteins and Other Systemic Responses to Inflammation
Gabay, C., & Kushner, I. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902113400607 · Cited by 6,734 · cited 1×
“19 Upon activation, these intracytoplasmic molecular cascades upregulate the transcription of pro-inflammatory cytokine genes 22 and, consequently, the synthesis of acute-phase inflammatory mediators 49–51 and activation of c-Jun N-terminal kinase (JNK) and inhibitor of NF κ B kinase-β (IKK).”
BackgroundPearson, T. A., Mensah, G. A., Alexander, R. W., Anderson, J. L., Cannon, R. O., Criqui, M., Fadl, Y. Y., Fortmann, S. P., Hong, Y., Myers, G. L., et al. (2003) · Circulation · doi:10.1161/01.cir.0000052939.59093.45 · Cited by 6,401 · cited 1×
“The magnitude and rapidity of its induction and its cooperative role in innate immune response, as well as its ease of measurement, all make CRP a common marker for inflammation.(108) Furthermore, CRP is invariably correlated with various parameters relevant to diabetes, including obesity, lipogenesis, and adiponectin.”
BackgroundGlobal and societal implications of the diabetes epidemic
Zimmet, P., Alberti, K. G. M. M., & Shaw, J. (2001) · Nature · doi:10.1038/414782a · Cited by 5,883
Inflammation and insulin resistance
Shoelson, S. E. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29069 · Cited by 4,769
Obesity induces a phenotypic switch in adipose tissue macrophage polarization
Lumeng, C. N., Bodzin, J. L., & Saltiel, A. R. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29881 · Cited by 4,664 · cited 2×
“Subsequent activation of macrophages towards an inflammatory phenotype results in cytokine synthesis and release.(24,25) Cytokines then downregulate major anabolic cascades involved in insulin signaling and mediate adipocyte insulin resistance.”
BackgroundC-Reactive Protein, Interleukin 6, and Risk of Developing Type 2 Diabetes Mellitus
Pradhan, A. D. (2001) · JAMA · doi:10.1001/jama.286.3.327 · Cited by 4,433
Inflammation, stress, and diabetes
Wellen, K. E., & Hotamisligil, G. S. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25102 · Cited by 4,143
TLR4 links innate immunity and fatty acid-induced insulin resistance
Shi, H., Kokoeva, M. V., Inouye, K., Tzameli, I., Yin, H., & Flier, J. S. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28898 · Cited by 3,690 · cited 1×
“48 Binding to PRRs gives rise to inflammatory responses by mediating downstream transcriptional events that activate nuclear factor-κ B (NF κ B) and activator protein-1 (AP-1) and their pathways (see Figure 1).”
BackgroundHotamisligil, G. S., Arner, P., Caro, J. F., Atkinson, R. L., & Spiegelman, B. M. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117936 · Cited by 3,543 · cited 2×
“Ultimately, this contributes to disruption of whole-body insulin sensitivity and impairs glucose homeostasis.(26) In addition to their effect on insulin resistance, cytokines also act on the liver to increase the production of very-low density lipoproteins (VLDL), leading to the characteristic diabetic dyslipidemia,(2…”
BackgroundA central role for JNK in obesity and insulin resistance
Hirosumi, J., Tuncman, G., Chang, L., Görgün, C. Z., Uysal, K. T., Maeda, K., Karin, M., & Hotamisligil, G. S. (2002) · Nature · doi:10.1038/nature01137 · Cited by 3,359 · cited 1×
“Transcriptional upregulation of these genes promotes both localized and systemic inflammatory responses(60) to mediate fatty liver and insulin resistance.(101) The interaction between IL-6 and the insulin pathway also involves mediating the interaction between SOCS proteins and the INSR.”
BackgroundThe Continuing Epidemics of Obesity and Diabetes in the United States
Mokdad, A. H. (2001) · JAMA · doi:10.1001/jama.286.10.1195 · Cited by 2,730
Hotamisligil, G. S., Peraldi, P., Budavari, A., Ellis, R., White, M. F., & Spiegelman, B. M. (1996) · Science · doi:10.1126/science.271.5249.665 · Cited by 2,630
Protection from obesity-induced insulin resistance in mice lacking TNF-α function
Uysal, K. T., Wiesbrock, S. M., Marino, M. W., & Hotamisligil, G. S. (1997) · Nature · doi:10.1038/39335 · Cited by 2,234
Impaired Mitochondrial Activity in the Insulin-Resistant Offspring of Patients with Type 2 Diabetes
Petersen, K. F., Dufour, S., Befroy, D., Garcia, R., & Shulman, G. I. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031314 · Cited by 2,193
Inflammation: the link between insulin resistance, obesity and diabetes
Dandona, P. (2004) · Trends in Immunology · doi:10.1016/j.it.2003.10.013 · Cited by 2,170 · cited 2×
“Extensive experimental, clinical and epidemiological studies have linked obesity causally to the activation of inflammatory signaling pathways and to the subsequent manifestations of T2DM.(7,29,30) This relationship may facilitate the development of preventive measures for the disease at the early stages, as well as i…”
BackgroundYuan, M., Konstantopoulos, N., Lee, J., Hansen, L., Li, Z.-W., Karin, M., & Shoelson, S. E. (2001) · Science · doi:10.1126/science.1061620 · Cited by 1,884 · cited 1×
“Indeed, heterozygous deletion in IKKβ (ie, in IKKβ+/- mice) improved insulin sensitivity in obese mice target cells.(57) In addition, TNF-α upregulates the expression of suppressor of cytokine signaling (SOCS) proteins, which bind to IRS-1 to mediate its degradation.”
BackgroundInflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?
Yudkin, J. S., Kumari, M., Humphries, S. E., & Mohamed-Ali, V. (2000) · Atherosclerosis · doi:10.1016/s0021-9150(99)00463-3 · Cited by 1,775
Inflammatory Cytokines and the Risk to Develop Type 2 Diabetes
Spranger, J., Kroke, A., Möhlig, M., Hoffmann, K., Bergmann, M. M., Ristow, M., Boeing, H., & Pfeiffer, A. F. H. (2003) · Diabetes · doi:10.2337/diabetes.52.3.812 · Cited by 1,493
Aguirre, V., Uchida, T., Yenush, L., Davis, R., & White, M. F. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.12.9047 · Cited by 1,487 · cited 3×
“Interestingly, direct exposure of insulin-target cells to cytokines such as TNF-α and IL-1β also activates JNK and IKK,(56) making these factors a common link in the molecular mechanism of lipotoxicity and inflammation leading to insulin resistance and T2DM via post-transcriptional actions.(53) Indeed, heterozygous de…”
BackgroundInflammation and Activated Innate Immunity in the Pathogenesis of Type 2 Diabetes
Pickup, J. C. (2004) · Diabetes Care · doi:10.2337/diacare.27.3.813 · Cited by 1,414
Kirpichnikov, D., McFarlane, S. I., & Sowers, J. R. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-1-200207020-00009 · Cited by 1,084 · cited 1×
“Sulfonylureas increase insulin release from pancreatic β-cells,(130) whereas metformin suppresses glucose production in the liver and increases insulin sensitivity in peripheral tissues.(131) Glitazones bind to peroxisome proliferator-activated receptors (PPARs), initiating transcriptional activity that leads to impro…”
BackgroundNguyen, M. T. A., Favelyukis, S., Nguyen, A.-K., Reichart, D., Scott, P. A., Jenn, A., Liu-Bryan, R., Glass, C. K., Neels, J. G., & Olefsky, J. M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m706762200 · Cited by 1,035
Inflammatory Markers and Risk of Developing Type 2 Diabetes in Women
Hu, F. B., Meigs, J. B., Li, T. Y., Rifai, N., & Manson, J. E. (2004) · Diabetes · doi:10.2337/diabetes.53.3.693 · Cited by 788 · cited 1×
“Numerous prospective studies demonstrate an independent positive association of CRP with the presence of T2DM 38,75,76,109–114 while others show no association after adjustment for adiposity and insulin resistance.”
BackgroundPeroxisome proliferator-activated receptors in inflammation control
Delerive, P., Fruchart, J., & Staels, B. (2001) · Journal of Endocrinology · doi:10.1677/joe.0.1690453 · Cited by 755 · cited 1×
“Accordingly, glitazones reduced serum levels of CRP (30% reduction in 1 week), PAI-1, TNF-α and other inflammatory markers.(7,133) Statins, metformin and sulfonylureas have comparable anti-inflammatory activity.”
BackgroundSubcutaneous Adipose Tissue Releases Interleukin-6, But Not Tumor Necrosis Factor- , in Vivo
Mohamed-Ali, V. (1997) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.12.4196 · Cited by 717
Biomarkers of Endothelial Dysfunction and Risk of Type 2 Diabetes Mellitus
Meigs, J. B. (2004) · JAMA · doi:10.1001/jama.291.16.1978 · Cited by 643
Inflammation and the IKKβ/IκB/NF-κB axis in obesity- and diet-induced insulin resistance
Shoelson, S. E., Lee, J., & Yuan, M. (2003) · International Journal of Obesity · doi:10.1038/sj.ijo.0802501 · Cited by 474
Lagathu, C., Bastard, J.-P., Auclair, M., Maachi, M., Capeau, J., & Caron, M. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.10.013 · Cited by 385
Rieusset, J., Bouzakri, K., Chevillotte, E., Ricard, N., Jacquet, D., Bastard, J.-P., Laville, M., & Vidal, H. (2004) · Diabetes · doi:10.2337/diabetes.53.9.2232 · Cited by 200 · cited 1×
“101 104 Therefore, IL-6 antagonists and factors that target JNK and IKK may offer promising preventive and/or therapeutic approaches to improve insulin sensitivity.”
BackgroundObesity, Metabolic Syndrome, and Type 2 Diabetes: Inflammatory Basis of Glucose Metabolic Disorders
Pradhan, A. (2007) · Nutrition Reviews · doi:10.1301/nr.2007.dec.s152-s156 · Cited by 145
Novel biochemical risk factors for type 2 diabetes: pathogenic insights or prediction possibilities?
Sattar, N., Wannamethee, S. G., & Forouhi, N. G. (2008) · Diabetologia · doi:10.1007/s00125-008-0954-7 · Cited by 143
Cited by
Obesity and inflammation: the linking mechanism and the complications
Ellulu, M. S., Patimah, I., Khaza’ai, H., Rahmat, A., & Abed, Y. (2017) · Archives of Medical Science · doi:10.5114/aoms.2016.58928 · Cited by 1,982
Oxidative Stress in Type 2 Diabetes: Impacts from Pathogenesis to Lifestyle Modifications
Caturano, A., D’Angelo, M., Mormone, A., Russo, V., Mollica, M. P., Salvatore, T., Galiero, R., Rinaldi, L., Vetrano, E., Marfella, R., et al. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45080420 · Cited by 579
Diabesity: an overview of a rising epidemic
Farag, Y. M. K., & Gaballa, M. R. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq576 · Cited by 320
Ding, L.-N., Ding, W.-Y., Ning, J., Wang, Y., Yan, Y., & Wang, Z.-B. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.770861 · Cited by 49
Zulaikhah, S. T., Wahyuwibowo, J., Suharto, M. N., Enggartiasto, B. H., Raka Ortanto, M. I., & Pratama, A. A. (2020) · Pharmacognosy Journal · doi:10.5530/pj.2021.13.63 · Cited by 10
Metadata
- Authors
- Badawi
- Venue
- Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
- Publisher
- Informa UK Limited
- Published
- 2010-05
- Volume
- 3
- Pages
- 173
- ISSN
- 1178-7007 (ISSN-L)
- OpenAlex
- W2023863507
- Cited by
- 177
- References
- 33
- FWCI
- 7.97
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.